Loe said that while Fast Track status doesn’t guarantee PMN310 will succeed in future Phase II or III Alzheimer’s trials, it ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present the latest findings on lecanemab (Leqembi®), including four-year efficacy and safety data and data on the subcutaneous ...

Alzheimer’s disease is a type of dementia, and there are more than 7 million Americans living with it. According to the ...

Lecanemab presentations to include long-term Clarity AD data, real-world treatment insights, and a subcutaneous formulation ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the drug discovery research for lecanemab (product name Leqembi®), an antibody indicated for early Alzheimer's ...

The Bioindustry Award, now marking its 9th year, recognizes achievements that have significantly contributed to the development of the bioindustry or are expected to contribute to its future growth.

Dementia is a condition that affects memory, thinking, and behavior, and it tends to get worse over time. While there is ...

HEALTH campaigners fear the country is sleepwalking into a dementia care crisis. Alzheimer Scotland bosses have launched a ...

Andrew Frank and Katherine C. Pearson, QUOI MediaAlzheimer’s disease is an insidious and relentless loss of memory and thinking, accompanied by a gradual ...

The new dosing schedule with a more gradual titration significantly lowered incidence of ARIA-E in the TRAILBLAZER-ALZ 6 trial.

Biogen has been trying to build up its R&D pipeline as it faces increased competition for its biggest-selling products like Spinraza (nusinersen) for spinal muscular atrophy (SMA) and its multiple ...

The health ministry is expected to cut the official price of the drug by up to 15% from the current level of about ¥3 million ...